Sugi Predict

Sugi Predict / Compounds / SCHEMBL7920632

SCHEMBL7920632

SCHEMBL7920632

Cc1ccn2nc(C)nc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.42
▸ ALDH1A1 P00352 6/20 0.42
▸ PDE10A Q9Y233 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ DNMT1 P26358 1/20 0.39
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ AHR P35869 1/20 0.36
▸ POLB P06746 3/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ COMT P21964 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ USP7 Q93009 1/20 0.35
▸ GAA P10253 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL616699 0.80 AHR (0.57) KDM4EALDH1A1PDE10ASMN1; SMN2TP53
SCHEMBL14007016 0.80 PIK3CG (0.38) KDM4EALDH1A1PDE10ASMN1; SMN2TP53
SCHEMBL20605163 0.80 KDM4E (0.41) KDM4EALDH1A1PDE10ASMN1; SMN2TP53
SCHEMBL30456487 0.80 KDM4E (0.40) KDM4EALDH1A1PDE10ASMN1; SMN2TP53
SCHEMBL31257450 0.80 AHR (0.34) KDM4EALDH1A1PDE10ARAB9AAHR
SCHEMBL24348565 0.80 AHR (0.34) KDM4EALDH1A1PDE10AAHRL3MBTL1
SCHEMBL9615525 0.80 KDM4E (0.40) KDM4EALDH1A1PDE10ASMN1; SMN2TP53
SCHEMBL16979292 0.80 KDM4E (0.40) KDM4EALDH1A1PDE10ASMN1; SMN2NPC1
SCHEMBL15774157 0.80 PIK3CG (0.47) KDM4EALDH1A1PDE10ASMN1; SMN2TP53
Hydrochloric Acid SCHEMBL22124375 0.79 PIK3CG (0.37) KDM4EALDH1A1PDE10ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137329-A1 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2024-06-27 — — WO disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
WO-2023114200-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 — — WO disclosed
WO-2023114198-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 — — WO disclosed
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY 2023-06-15 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2023081845-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2023034812-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 — — WO disclosed
WO-2023014296-A2 MOLECULAR GLUE AND SALL4 DEGRADER NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-02-09 — — WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
WO-2011149856-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2011-12-01 — — WO disclosed
WO-2011136385-A1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-03 — — WO disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 — — EP disclosed
WO-2010065668-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2010-06-10 — — WO disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-27 — — US disclosed
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-27 — — US disclosed
WO-2007034251-A1 AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2007-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KDM4E 3961/4885ALDH1A1 4544/4885PDE10A 534/4885
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands CCR3, CCR1, CCR4 KDM4E 3442/4885ALDH1A1 1778/4885PDE10A 2381/4885
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 CHRM5, CHRM1, CHRM2 KDM4E 1188/4885ALDH1A1 622/4885PDE10A 1093/4885
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB KDM4E 1344/4885ALDH1A1 583/4885PDE10A 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.